Peptide Therapeutics intermediate
Milestone 016: Oligopeptide Research Reference
2021: Semaglutide (Wegovy) approved for obesity. STEP trials show 15% weight loss. This peptide or oligopeptide is studied for its biological activity, struc...
By Encyclopeptide Editorial | 1 min read
milestone-016 peptide research
Overview
2021: Semaglutide (Wegovy) approved for obesity. STEP trials show 15% weight loss.
Clinical Significance
This topic has important implications for peptide research and clinical applications.
References
- Encyclopeptide Database. “Milestone 016” monograph. encyclopeptide.com.
Test Your Knowledge
Reinforce what you learned about Milestone 016: Oligopeptide Research Reference with interactive quizzes on Wikipept.
Take a Quiz on Wikipept